David Hartford

The Protenx™ line of products for food & beverage and consumer packaged goods manufacturers: Repurposing food molecules, mediated by ectopic receptors, to induce physiologic benefits similar to drugs. Designed as ingredients for new or existing consumer products, to induce weight loss, reduce blood sugar and more. Applying AI to biology to understand ectopic receptors and the physiologic pathways they affect, as well as understanding of olfactory and taste receptors.

Jaxon is making AI trustworthy. AI has a propensity to fabricate responses – Jaxon keeps them honest. Based on R&D with the US Department of Defense, Jaxons proprietary DSAIL (Domain-Specific AI Language) technology applies formal constraints and assertions to verify responses. Now AI can be relied upon for mission-critical applications.

Our Mission: Urgently impact climate change, at scale, by harnessing the power of Asparagopsis seaweed to reduce methane from cows. This is because we believe: * Climate change is real. Humanity is running out of time to act. Agriculture/methane is a significant contributor to climate change. * Nature can inspire and technology can deliver a meaningful difference. Seaweed is an unrealized resource that nature has provided to reduce methane in cows. * We are realists about convincing the world to do things differently. We want to make change as easy as possible. * We are certain that we can make a difference by bringing individuals, communities, governments and industry together. The company’s bold vision is for Zero Methane Agriculture by bending the climate curve. because cutting methane will significantly slow short-term global warming. CH4’s urgent initiative is to cut methane emissions from livestock by making available to the world sustainable, globally-scaled products containing a unique seaweed. This special seaweed, Asparagopsis, has over 10 years of research behind it and has shown effects of 60-90% reduction in methane emissions from both dairy and beef cattle and sheep. As we, at CH4 Global, work to make Asparagopsis products real, we are committed to doing this in a way that makes it easy for farmers to adopt and that will benefit communities where we aqua-farm. We are collaborating with local communities to ensure that all can benefit from our work. Our Management Team and Advisory Board come with significant research, development, marketing, large-scale production, distribution and investment experience in major global companies. We are based in USA, New Zealand and Australia.

Established in 2018, xCures is a pioneer in healthcare data management. Our primary focus is on achieving data completeness and providing real-time data access. We gather and standardize detailed medical records from various healthcare sources, utilizing direct retrieval from US institutions, patient portals, and electronic health exchanges. The collected data is digitized, organized, and examined using Natural Language Processing to efficiently identify features, resulting in a comprehensive longitudinal patient journey that covers everything from genomics to social determinants of health. We have processed over 140 million records from thousands of different medical practices and implemented our technology for a significant number of patients. All the collected data elements are thoroughly annotated in a central Electronic Data Capture (EDC) system to ensure standardization and ongoing accuracy. Through a range of tools and products, xCures offers clinically actionable, real-time insights that support the care of patients, providers, and partners. For further information, please contact info@xcures.com or visit http://www.xcures.com.

The Protenx™ line of products for food & beverage and consumer packaged goods manufacturers: Repurposing food molecules, mediated by ectopic receptors, to induce physiologic benefits similar to drugs. Designed as ingredients for new or existing consumer products, to induce weight loss, reduce blood sugar and more. Applying AI to biology to understand ectopic receptors and the physiologic pathways they affect, as well as understanding of olfactory and taste receptors.

Jaxon is making AI trustworthy. AI has a propensity to fabricate responses – Jaxon keeps them honest. Based on R&D with the US Department of Defense, Jaxons proprietary DSAIL (Domain-Specific AI Language) technology applies formal constraints and assertions to verify responses. Now AI can be relied upon for mission-critical applications.

Our Mission: Urgently impact climate change, at scale, by harnessing the power of Asparagopsis seaweed to reduce methane from cows. This is because we believe: * Climate change is real. Humanity is running out of time to act. Agriculture/methane is a significant contributor to climate change. * Nature can inspire and technology can deliver a meaningful difference. Seaweed is an unrealized resource that nature has provided to reduce methane in cows. * We are realists about convincing the world to do things differently. We want to make change as easy as possible. * We are certain that we can make a difference by bringing individuals, communities, governments and industry together. The company’s bold vision is for Zero Methane Agriculture by bending the climate curve. because cutting methane will significantly slow short-term global warming. CH4’s urgent initiative is to cut methane emissions from livestock by making available to the world sustainable, globally-scaled products containing a unique seaweed. This special seaweed, Asparagopsis, has over 10 years of research behind it and has shown effects of 60-90% reduction in methane emissions from both dairy and beef cattle and sheep. As we, at CH4 Global, work to make Asparagopsis products real, we are committed to doing this in a way that makes it easy for farmers to adopt and that will benefit communities where we aqua-farm. We are collaborating with local communities to ensure that all can benefit from our work. Our Management Team and Advisory Board come with significant research, development, marketing, large-scale production, distribution and investment experience in major global companies. We are based in USA, New Zealand and Australia.

UK Private Capital (formerly the British Private Equity and Venture Capital Association - BVCA) is the association of the UK private capital industry. We represent 600 firms including the wider ecosystem of professional advisers and investors.   Private capital consists of private equity and venture capital which make long-term investments to grow British businesses and build a better economy. Private credit and venture debt provide active and engaged debt finance to businesses.  The private capital industry backs 13,000 UK businesses, nine in 10 of which are small or medium-sized enterprises. Businesses backed by the industry employ 2.5 million people across the UK and contribute 7% to GDP.  In 2024, £29.4bn was invested by private capital into UK businesses in sectors across the UK economy, ranging from consumer products to emerging technology. This increased investment has fuelled the growth of businesses across the UK, with six in ten (58%) of the businesses backed in 2024, located outside of the capital.  These investments are long term, with an average investment period of six years, in contrast to less than a year in public markets.  UK-based private capital specialists have raised £190bn of funds, known as dry powder, which is expected to be invested over the next three to five years.   The industry invests for a better future by backing some of the UK’s best loved businesses, developing the companies of the future and delivering solutions to global problems. 

Established in 2018, xCures is a pioneer in healthcare data management. Our primary focus is on achieving data completeness and providing real-time data access. We gather and standardize detailed medical records from various healthcare sources, utilizing direct retrieval from US institutions, patient portals, and electronic health exchanges. The collected data is digitized, organized, and examined using Natural Language Processing to efficiently identify features, resulting in a comprehensive longitudinal patient journey that covers everything from genomics to social determinants of health. We have processed over 140 million records from thousands of different medical practices and implemented our technology for a significant number of patients. All the collected data elements are thoroughly annotated in a central Electronic Data Capture (EDC) system to ensure standardization and ongoing accuracy. Through a range of tools and products, xCures offers clinically actionable, real-time insights that support the care of patients, providers, and partners. For further information, please contact info@xcures.com or visit http://www.xcures.com.